Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and Food Effect of Milvexian in Healthy Participants
NCT04965389Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in venous thromboembolism (VTE) and ischemic stroke (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Absolute Bioavailability (F) at Day 1. Started Jul 2021; status: completed.
02
Drugs
milvexian
03
Conditions
venous thromboembolism (VTE)ischemic stroke
Beyond the preview
Go deeper on NCT04965389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965389.